狼疮性肾炎：当前问题
Lupus nephritis: current issues.
作者信息
Mavragani C P, Moutsopoulos H M
机构信息
Department of Pathophysiology, School of Medicine, National University of Athens, Greece.
出版信息
Ann Rheum Dis. 2003 Sep;62(9):795-8. doi: 10.1136/ard.62.9.795.
Abstract
Despite the development of new modalities, cyclophosphamide (CYC) remains the preferred initial treatment for severe proliferative lupus nephritis. Controversies continue about the best route, dosage, and duration of CYC treatment. For recalcitrant disease, new immunosuppressive and immunomodulating agents, immunoablative high dose CYC, nucleoside analogues, apheresis, and the biological response modifiers can be considered.
摘要
尽管有了新的治疗方法，但环磷酰胺（CYC）仍然是重度增殖性狼疮性肾炎的首选初始治疗药物。关于CYC治疗的最佳途径、剂量和疗程仍存在争议。对于难治性疾病，可以考虑使用新的免疫抑制和免疫调节药物、免疫清除大剂量CYC、核苷类似物、血浆置换以及生物反应调节剂。
相似文献
1
Lupus nephritis: current issues.狼疮性肾炎：当前问题
Ann Rheum Dis. 2003 Sep;62(9):795-8. doi: 10.1136/ard.62.9.795.
2
Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.支持观点：钙调磷酸酶抑制剂在狼疮肾炎治疗中的应用。
Nephrol Dial Transplant. 2016 Oct;31(10):1561-6. doi: 10.1093/ndt/gfw289. Epub 2016 Sep 1.
3
Immunosuppressive treatment for proliferative lupus nephritis.增殖性狼疮性肾炎的免疫抑制治疗
Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4.
4
[Immunosuppresive treatment in patients with lupus glomerulonephritis. Review of adverse events].[狼疮性肾小球肾炎患者的免疫抑制治疗。不良事件综述]
Reumatol Clin. 2006 Nov;2(6):313-21. doi: 10.1016/S1699-258X(06)73067-4. Epub 2008 Dec 10.
5
Therapeutic options for resistant lupus nephritis.难治性狼疮性肾炎的治疗选择。
Semin Arthritis Rheum. 2006 Oct;36(2):71-81. doi: 10.1016/j.semarthrit.2006.04.008. Epub 2006 Jul 12.
6
Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.霉酚酸酯与环磷酰胺治疗弥漫性增殖性狼疮性肾炎患者的疗效比较
Chin Med J (Engl). 2002 May;115(5):705-9.
7
Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.环磷酰胺治疗弥漫性增殖性狼疮性肾炎的长期预后
Am J Med. 2006 Apr;119(4):355.e25-33. doi: 10.1016/j.amjmed.2005.08.045.
8
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.狼疮性肾炎的免疫抑制治疗：欧洲狼疮性肾炎试验，一项低剂量与高剂量静脉注射环磷酰胺的随机试验。
Arthritis Rheum. 2002 Aug;46(8):2121-31. doi: 10.1002/art.10461.
9
Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.比较儿童关节炎和风湿病研究联盟针对青少年增殖性狼疮性肾炎诱导治疗的共识治疗方案的初步研究。
Pediatr Rheumatol Online J. 2018 Oct 22;16(1):65. doi: 10.1186/s12969-018-0279-0.
10
Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?霉酚酸酯是否应替代环磷酰胺作为重度狼疮肾炎的一线治疗药物？
Kidney Int. 2012 Dec;82(12):1256-60. doi: 10.1038/ki.2012.203. Epub 2012 May 30.
引用本文的文献
1
Clinical and laboratory predictors of distinct histopathogical features of lupus nephritis.狼疮性肾炎不同组织病理学特征的临床和实验室预测指标
Medicine (Baltimore). 2015 May;94(21):e829. doi: 10.1097/MD.0000000000000829.
2
Novel therapeutic agents in clinical development for systemic lupus erythematosus.正在临床开发用于系统性红斑狼疮的新型治疗药物。
BMC Med. 2013 May 3;11:120. doi: 10.1186/1741-7015-11-120.
3
Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.沙特阿拉伯利雅得624例系统性红斑狼疮患者中的狼疮性肾炎。
Rheumatol Int. 2009 Jul;29(9):1057-67. doi: 10.1007/s00296-009-0905-8. Epub 2009 Apr 21.
4
[Glucocorticoid therapy in collagen diseases diseases].[胶原病中的糖皮质激素治疗]
Z Rheumatol. 2005 Apr;64(3):162-9. doi: 10.1007/s00393-005-0721-9.
本文引用的文献
1
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.短期使用BG9588（抗CD40配体抗体）可改善增殖性狼疮性肾小球肾炎患者的血清学活性并减少血尿。
Arthritis Rheum. 2003 Mar;48(3):719-27. doi: 10.1002/art.10856.
2
Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients.重症难治性狼疮的造血干细胞移植。15例患者5年后的分析。
Arthritis Rheum. 2002 Nov;46(11):2917-23. doi: 10.1002/art.10594.
3
4
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.狼疮性肾炎的免疫抑制治疗：欧洲狼疮性肾炎试验，一项低剂量与高剂量静脉注射环磷酰胺的随机试验。
Arthritis Rheum. 2002 Aug;46(8):2121-31. doi: 10.1002/art.10461.
5
What do we know about lupus membranous nephropathy? An analytic review.关于狼疮性膜性肾病我们了解多少？一项分析性综述。
Arthritis Rheum. 2002 Aug;47(4):450-5. doi: 10.1002/art.10417.
6
Novel therapeutic agents for systemic lupus erythematosus.系统性红斑狼疮的新型治疗药物。
Curr Opin Rheumatol. 2002 Sep;14(5):515-21. doi: 10.1097/00002281-200209000-00006.
7
"Black swan in the kidney": renal involvement in the antiphospholipid antibody syndrome.“肾脏中的黑天鹅”：抗磷脂抗体综合征的肾脏受累情况
Kidney Int. 2002 Sep;62(3):733-44. doi: 10.1046/j.1523-1755.2002.00500.x.
8
Pathogenesis of lupus.狼疮的发病机制。
Arthritis Rheum. 2002 Jun 15;47(3):343-5. doi: 10.1002/art.10380.
9
Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus.系统性红斑狼疮患者静脉注射环磷酰胺后发生骨髓毒性的风险。
Rheumatology (Oxford). 2002 Jul;41(7):780-6. doi: 10.1093/rheumatology/41.7.780.
10
Demographic differences in the development of lupus nephritis: a retrospective analysis.狼疮性肾炎发展中的人口统计学差异：一项回顾性分析。
Am J Med. 2002 Jun 15;112(9):726-9. doi: 10.1016/s0002-9343(02)01118-x.
Zotero 插件